Based in the Biotech Cluster Rhine-Neckar, Phenex Pharmaceuticals specializes in small-molecule drug discovery for liver and gastrointestinal diseases, and has recently expanded into cancer therapy. Their expertise lies in identifying novel molecular mechanisms and translating them into proprietary therapeutic small molecules. Their services include developing therapies that target bile acids, prevent liver diseases, and treat chronic inflammation. The company's most advanced drug, Cilofexor, is currently in phase 2 clinical development by Gilead Sciences. For more information, visit their website at www.phenex-pharma.com or follow them on Twitter at @PhenexPharma.